TSXV:BTI.H - Post by User
Comment by
Boomskidon Jan 27, 2023 12:48pm
227 Views
Post# 35250443
RE:So do we assume the JNJ option expired?
RE:So do we assume the JNJ option expired? The J&J agreement was likely all about J&J exploring something with xB3 and about xB3. Such agreements usually prevent the licensee from doing anything beyond that. A new agreement is required to do more work and to advance anything worth advancing.
So how might such an agreement resolve itself?
- Was xB3 successful in its job of transporting its J&J payload? (Almost certainly it was. After dozens of successful payload deliveries, it would be a shock if xB3 failed to do it again.)
- If xb3 was successful with delivery, then did the payload work?
- Was the payload safe?
- Did xB3 transport affect the payload?
- Were there off-target delivery issues? (related to LRP-1 receptors)
- Does the payload or xB3-payload need more research?
- Was the study more of a study to inform J&J about the capabilities? Does J&J otherwise know what they might do with xB3?
- Is Bioasis's current financial state and possible sale or collapse causing J&J to postpone decisions relating to xB3?
- Does the xB3-Payload have potential commercial value?
- Is J&J ready or willing to place the xB3 drug in its pipeline at this time?
If J&J enters a deal with Bioasis then we have an answer.
If a deal does not happen and the option date is passed, it could mean anything from bad to fantastic. Whatever is going on, or not going on, it is very unlikely that it has anything to do with xB3.
jd